AVELUMAB

Brand name:

• Bavencio®

Pharmaceutical company:

Merck Healthcare Pty Ltd

Condition/indication:
(therapeutic use)

• Urothelial carcinoma

PBAC Submission type:

Change to listing (Major Submission)

Comment:

--

Public Summary Document:

PBAC Public Summary Documents – March 2022

Related medicines:

• AVELUMAB

Submission received for:

March 2022 PBAC meeting

Opportunity for consumer comment:

Open 23/12/2020 and close 10/02/2021 (see PBS Website)

PBAC meeting:

Held on 09/03/2022

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

20/05/2022

Lodgement of required documentation:

27/05/2022

Acceptance of complete documentation:

Accepted

Agreement to listing arrangements:

Commenced on 02/08/2022

Status:

Finalised

Government processes:

Commenced on 05/08/2022

Medicine listed on the PBS:

01/10/2022 (see PBS schedule)

---